Atorvastatin Calcium
Brand names: Atorvaliq, Atorvastatin Calcium, Lipitor
Part of: Statins
At a glance
- Medicare prescriptions, 2024
- 71,665,928
- Medicare drug cost
- $742.9M
- Average cost per prescription
- $10.37
- Clinicians who prescribed it
- 366,083
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Atorvastatin Calcium Tablets are indicated: To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia. Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia Hypertriglyceridemia Atorvastatin calcium tablets
From the FDA-approved prescribing information (label dated July 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 32.6%
- Internal Medicine 27.9%
- Nurse Practitioners 16.5%
- Cardiology 7.1%
- Physician Assistants 5.6%
- Interventional Cardiology 2.5%
- General Practice 1.7%
- Geriatric Medicine 1.5%
- Endocrinology & Diabetes 0.9%
- Hospitalist 0.7%
- Nephrology (Kidney) 0.5%
- Cardiac Electrophysiology 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 34% from 2019 to 2024.
Biggest change by state since 2019
- Vermont +54%
- Wyoming +50%
- Kansas +48%
- Montana +46%
- Utah +46%
- Puerto Rico (smallest change) +21%
- Rhode Island (smallest change) +22%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Accord Healthcare Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | white oval tablet, 10 mm | FF1 |
| 20 mg | white oval tablet, 12 mm | FF2 |
| 40 mg | white oval tablet, 15 mm | FF3 |
| 80 mg | white oval tablet, 19 mm | FF4 |
Kesin Pharma Corporation
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | white oval tablet, 10 mm | 10 ATS |
| 20 mg | white oval tablet, 12 mm | 20 ATS |
| 80 mg | white oval tablet, 19 mm | 80 ATS |
Northstar Rx LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | white oval tablet, 9 mm | APO A10 |
| 20 mg | white oval tablet, 11 mm | APO ATV20 |
| 40 mg | white oval tablet, 14 mm | APO ATV40 |
| 80 mg | white oval tablet, 19 mm | APO ATV80 |
Nucare Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 40 mg | white oval tablet, 15 mm | 40 A55 |
Viatris Specialty LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | white oval tablet, 10 mm | 10 VLE 155 |
| 20 mg | white oval tablet, 12 mm | 20 VLE 156 |
| 40 mg | white oval tablet, 15 mm | 40 VLE 157 |
| 80 mg | white oval tablet, 19 mm | 80 VLE 158 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $2,177 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Cmp Pharma, Inc. $2,110
- Mylan Inc. $67
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
8 recalls since 2020
- Sep 2025 · Ascend Laboratories, LLC · Class II
Failed Dissolution Specifications - Mar 2025 · Biocon Pharma Inc · Class II
Failed dissolution specifications: lower than specifications - Mar 2023 · Northwind Pharmaceuticals LLC · Class II
CGMP Deviations - Feb 2023 · Accord Healthcare, Inc. · Class II
CGMP Deviations: recalling drug products following an FDA inspection. - Mar 2022 · Dr. Reddy's Laboratories, Inc. · Class III
Failed Impurities/Degradation Specifications: Out of Specification results for related substance. - Jun 2021 · Dr. Reddy's Laboratories, Inc. · Class III
Failed Impurities/Degradation Specifications: due to presence of ATV cyclo IP and FP impurities - May 2021 · Dr. Reddy's Laboratories, Inc. · Class III
Failed Impurities -Degradation Specifications:due to presence of ATV cyclo IP and FP impurities - Feb 2021 · Dr. Reddy's Laboratories, Inc. · Class III
Failed Impurities/Degradation Specifications:presence of ATV cyclo IP and FP, Dihydroxy epoxy and Dieto epoxy impurities
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.